X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
naloxegol (81) 81
opioid-induced constipation (51) 51
index medicus (45) 45
humans (44) 44
pharmacology & pharmacy (32) 32
analgesics, opioid - adverse effects (31) 31
constipation (30) 30
chronic noncancer pain (29) 29
constipation - chemically induced (29) 29
constipation - drug therapy (25) 25
efficacy (24) 24
safety (23) 23
methylnaltrexone (22) 22
prevalence (21) 21
male (20) 20
induced bowel dysfunction (19) 19
tolerability (19) 19
narcotic antagonists - therapeutic use (18) 18
adult (17) 17
double-blind (16) 16
female (16) 16
lubiprostone (16) 16
middle aged (16) 16
opioids (16) 16
pain (16) 16
pharmacokinetics (16) 16
narcotics (15) 15
laxatives (14) 14
naloxone (14) 14
noncancer pain (14) 14
morphinans - pharmacokinetics (13) 13
polyethylene glycols - pharmacokinetics (13) 13
alvimopan (12) 12
gastroenterology & hepatology (12) 12
narcotic antagonists - adverse effects (12) 12
quality of life (12) 12
morphinans - adverse effects (11) 11
narcotic antagonists - administration & dosage (11) 11
polyethylene glycols - adverse effects (11) 11
subcutaneous methylnaltrexone (11) 11
aged (10) 10
analysis (10) 10
morphinans - therapeutic use (10) 10
narcotic antagonists - pharmacokinetics (10) 10
polyethylene glycols - therapeutic use (10) 10
administration, oral (9) 9
analgesics (9) 9
analgesics, opioid - therapeutic use (9) 9
chronic pain (9) 9
chronic pain - drug therapy (9) 9
dose-response relationship, drug (9) 9
double-blind method (9) 9
induced constipation (9) 9
management (9) 9
morphinans - administration & dosage (9) 9
pamora (9) 9
pharmacology (9) 9
polyethylene glycols - administration & dosage (9) 9
receptors, opioid, mu - antagonists & inhibitors (9) 9
clinical neurology (8) 8
impairment (8) 8
laxatives - therapeutic use (8) 8
opioid receptor antagonist (8) 8
opioid‐induced constipation (8) 8
pathophysiology (8) 8
drug dosages (7) 7
medicine, general & internal (7) 7
naldemedine (7) 7
pain - drug therapy (7) 7
receptor antagonist (7) 7
area under curve (6) 6
cancer (6) 6
care and treatment (6) 6
complications and side effects (6) 6
controlled phase-3 trial (6) 6
naltrexone - analogs & derivatives (6) 6
treatment outcome (6) 6
young adult (6) 6
animals (5) 5
cross-over studies (5) 5
drug therapy (5) 5
gastrointestinal agents (5) 5
impact (5) 5
medicine & public health (5) 5
morphinans - pharmacology (5) 5
nonmalignant pain (5) 5
opioid (5) 5
opioid-induced bowel dysfunction (5) 5
oxycodone (5) 5
randomized controlled trials as topic (5) 5
severity (5) 5
validation (5) 5
advanced illness (4) 4
anesthesiology (4) 4
cancer pain (4) 4
constipation - physiopathology (4) 4
drug administration schedule (4) 4
drugs (4) 4
dysfunction (4) 4
gastroenterology (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Recenti Progressi in Medicina, ISSN 0034-1193, 11/2018, Volume 109, Issue 11, pp. E11 - E13
Journal Article
Journal of Opioid Management, ISSN 1551-7489, 05/2018, Volume 14, Issue 3, pp. 211 - 221
Efficacy and safety of naloxegol, a peripherally acting µ-opioid receptor antagonist that significantly reduces opioid-induced constipation (OIC), were... 
Naloxegol | Opioid-induced constipation | Baseline opioid characteristics
Journal Article
Internistische Praxis, ISSN 0020-9570, 04/2015, Volume 55, Issue 2, pp. 387 - 392
Journal Article
Journal of Cardiovascular Pharmacology and Therapeutics, ISSN 1074-2484, 7/2018, Volume 23, Issue 4, pp. 309 - 317
Background: Naloxegol is a novel selective, peripherally acting μ-opioid receptor antagonist for treating opioid-induced constipation (OIC) in patients with... 
PAMORA | cardiovascular safety | naloxegol | μ-opioid receptor antagonist | opioid-induced constipation
Journal Article
ORTHOPAEDIC NURSING, ISSN 0744-6020, 05/2019, Volume 38, Issue 3, pp. 209 - 211
Opioid-induced constipation is a known side effect of long-term opioid therapy and may contribute to increased healthcare utilization. Common laxatives such as... 
OPIOID-INDUCED CONSTIPATION | PHARMACOKINETICS | EFFICACY | SAFETY | NALOXEGOL | TOLERABILITY | NURSING | ORTHOPEDICS | RECEPTOR ANTAGONIST | CHRONIC NONCANCER PAIN | IMPAIRMENT
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 11/2018, Volume 58, Issue 11, pp. 1452 - 1460
AZD3241 is a potent and selective myeloperoxidase inhibitor potentially for the treatment of a number of neurodegenerative disorders, including multiple system... 
AZD3241 | MSA | PopPK | enterohepatic circulation | myeloperoxidase inhibition | NALOXEGOL | PHARMACOLOGY & PHARMACY | Atrophy | Regression models | Absorption | Neurodegenerative diseases | Variability | Gallbladder | Peroxidase | Exposure | Pharmacology | Regression analysis | Patients
Journal Article
NEUROGASTROENTEROLOGY AND MOTILITY, ISSN 1350-1925, 05/2019, Volume 31, Issue 5
Background Naldemedine (S-297995) is a peripherally acting mu-opioid receptor antagonist developed as a once-daily oral drug for opioid-induced constipation... 
MORPHINE | ACIDS | NALOXEGOL | opioid-induced constipation | PREVALENCE | NEUROSCIENCES | naldemedine | CLINICAL NEUROLOGY | opioid receptor | INHIBITION | PAIN | pharmacology | GASTROENTEROLOGY & HEPATOLOGY | WATER
Journal Article
by Wirz, S
LARYNGO-RHINO-OTOLOGIE, ISSN 0935-8943, 07/2019, Volume 98, Issue 7, pp. 473 - 479
More than 6 million people in Germany suffer from chronic pain which greatly impairs their wellbeing. Often the only therapeutic option is to use class 2 or 3... 
IMPACT | INDUCED CONSTIPATION | NALOXEGOL | OTORHINOLARYNGOLOGY | opioid-induced constipation | laxatives | opioid therapy | ADULTS | PAMORA | PREVALENCE | CHRONIC NONCANCER PAIN | PATHOPHYSIOLOGY
Journal Article
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, ISSN 0815-9319, 05/2019, Volume 34, Issue 5, pp. 818 - 829
Background and Aim Opioid-induced constipation (OIC) is a frequent adverse event (AE) that impairs patients' quality of life (QOL). Peripherally acting... 
PLACEBO | NONCANCER PAIN | NALOXEGOL | opioid-induced constipation | meta-analysis | CONTROLLED PHASE-3 TRIAL | RECEPTOR ANTAGONIST | peripherally acting mu-opioid antagonist | IMPACT | INDUCED BOWEL DYSFUNCTION | SUBCUTANEOUS METHYLNALTREXONE | DOUBLE-BLIND | ALVIMOPAN | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
Drugs, ISSN 0012-6667, 10/2012, Volume 72, Issue 14, pp. 1847 - 1865
Opioids are the most commonly prescribed medications to treat severe pain in the Western world. It has been estimated that up to 90% of American patients... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Naloxegol | Alvimopan | Methylnaltrexone-bromide | Gastrointestinal-disorders | Oxycodone | Fentanyl | Prucalopride | Transdermal | Gastrointestinal-motility | Oxycodonenaloxone | Tapentadol | Naloxone | Analgesics | Buprenorphine | Opioid-analgesics | Quality-of-life | Bevenopran | Lubiprostone | TD-1211 | Laxatives | Opioid-receptor-antagonists | ADL-7445 | Constipation | GASTROINTESTINAL TRANSIT | INDUCED CONSTIPATION | TRANSDERMAL FENTANYL | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | TOXICOLOGY | RELEASE ORAL MORPHINE | INTESTINAL TRANSIT | DRUG-DELIVERY SYSTEMS | BLOOD HORMONE LEVELS | CHLORIDE SECRETION | RECEPTOR ANTAGONIST | Severity of Illness Index | Narcotic Antagonists - administration & dosage | Gastroesophageal Reflux - physiopathology | Humans | Gastrointestinal Motility - drug effects | Narcotic Antagonists - adverse effects | Constipation - physiopathology | Gastroesophageal Reflux - chemically induced | Constipation - chemically induced | Dose-Response Relationship, Drug | Analgesics, Opioid - adverse effects | Analgesics, Opioid - administration & dosage | Constipation - drug therapy | Gastroesophageal Reflux - drug therapy | Dose-response relationship (Biochemistry) | Physiology, Pathological | Complications and side effects | Opioids | Causes of | Research
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 01/2016, Volume 81, Issue 1, pp. 89 - 100
Aims Naloxegol, a polyethylene glycol conjugated derivative of the opioid antagonist naloxone, is in clinical development for treatment of opioid‐induced... 
pharmacokinetics | nonmem | naloxegol | NKTR‐118 | Naloxegol | NKTR-118 | Nonmem | Pharmacokinetics | Area Under Curve | Models, Biological | Humans | Middle Aged | Morphinans - pharmacokinetics | Cytochrome P-450 CYP3A - physiology | Polyethylene Glycols - pharmacokinetics | Adult | Female | Male | Narcotic Antagonists - pharmacokinetics | Polyols | Analysis | Cytochrome P-450
Journal Article
Journal of Pain and Symptom Management, ISSN 0885-3924, 02/2018, Volume 55, Issue 2, pp. 468 - 479.e1
Journal Article
by Wirz, S
ZEITSCHRIFT FUR GASTROENTEROLOGIE, ISSN 0044-2771, 04/2017, Volume 55, Issue 4, pp. 394 - 400
More than 6 million people in Germany suffer from chronic pain which greatly impairs their wellbeing. Often the only therapeutic option is to use class 2 or 3... 
IMPACT | INDUCED CONSTIPATION | NALOXEGOL | opioid-induced constipation | laxatives | opioid therapy | ADULTS | PAMORA | PREVALENCE | GASTROENTEROLOGY & HEPATOLOGY | CHRONIC NONCANCER PAIN | PATHOPHYSIOLOGY
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.